drugset
Drugs / HTL0018318
last change Jan 2021 re-read 3 minutes ago

HTL0018318

Developed for
Alzheimer disease · Lewy body dementia
Investigated by
Nxera Pharma UK Limited · Allergan · Sosei

Trials 2

today NCT03592862 · Ph 2 NCT03456349 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03456349 Nov 2017 → Jul 2018 Alzheimer disease Nxera Pharma UK Limited Completed No outcome recorded
Phase 21 trial
Phase 2 NCT03592862 Jul 2019 → Jul 2020 Lewy body dementia Nxera Pharma UK Limited Withdrawn No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT03198624 Comparator May → Aug 2017 — Nxera Pharma UK Limited Completed No outcome recorded
Phase 1 NCT02958696 Comparator Oct 2016 → Jan 2017 — Nxera Pharma UK Limited Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2019-03-29 Nxera Pharma UK Limited Results 29th Ordinary General Meeting of Shareholders Q&A (Japanese only) nxera.life ↗

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as HTL0018318 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02958696 ↗
3

NCT03456349 ↗

NCT03198624 ↗

NCT03592862 ↗
Action Activate “HTL0018318 is a selective muscarinc M1 agonist.” NCT02958696 ↗
Route Oral “HTL0018318 when given by oral aqueous solution and in capsule formulation” NCT02958696 ↗